Stratos Wealth Partners LTD. Sells 30,504 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Stratos Wealth Partners LTD. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,014 shares of the biopharmaceutical company's stock after selling 30,504 shares during the period. Stratos Wealth Partners LTD.'s holdings in Gilead Sciences were worth $7,760,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. FMR LLC increased its stake in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the period. Pacer Advisors Inc. boosted its position in shares of Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock valued at $193,274,000 after purchasing an additional 1,793,145 shares during the period. Finally, International Assets Investment Management LLC increased its position in Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $2.00 during trading hours on Friday, reaching $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The business has a 50-day simple moving average of $93.04 and a 200 day simple moving average of $86.76. The stock has a market cap of $119.69 billion, a PE ratio of 1,067.11, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Oppenheimer lifted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Bank of America reiterated a "buy" rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Truist Financial raised their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 in the last ninety days. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.